Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive …
Full BRNS analysis →
Competitive advantage assessment
Key strengths
Scale Supporting ProfitabilityProfitability at scale is strong (score 0.76), demonstrating competitive advantages.
Operating Leverage in EffectOperating leverage is evident (score 0.84), with margins expanding over time.
Key risks
ROIC Below WACC or PeersROIC at 32.7th percentile suggests inefficient capital deployment.
Revenue Volatility Signals Weak StickinessRevenue volatility is high (stability score 0.04), suggesting weak customer stickiness.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Barinthus Biotherapeutics plc ranks #256 of 713
scored companies in Biotechnology by moat score — the top 36%.
The widest moat in the group is Royalty Pharma plc (RPRX)
at 85/100.
Moat scores for companies ranked near BRNS in Biotechnology
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 52
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 39
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 36
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 60
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 79
· 15% of the moat score
Scale matters only when it converts into economics.
What is Barinthus Biotherapeutics plc's moat score?
Barinthus Biotherapeutics plc (BRNS) scores 49 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #256 of 713 scored companies in Biotechnology, the top 36%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (79/100) and its weakest is Pricing Power (32/100).
How does Barinthus Biotherapeutics plc compare with other Biotechnology companies?
Barinthus Biotherapeutics plc ranks #256 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Generation Bio Co. (GBIO) at 49 just above it and Capricor Therapeutics, Inc. (CAPR) at 49 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.
Why is Barinthus Biotherapeutics plc scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Barinthus Biotherapeutics plc?
The Corporate Default template measures 6 defenses, and BRNS scores: Pricing Power (32), Cost Advantage (52), Customer Stickiness (39), Capital Efficiency (36), Resilience (60), Scale & Market Position (79). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.